Chimeric antigens for eliciting an immune response
    1.
    发明授权
    Chimeric antigens for eliciting an immune response 有权
    用于引发免疫应答的嵌合抗原

    公开(公告)号:US08029803B2

    公开(公告)日:2011-10-04

    申请号:US10365620

    申请日:2003-02-13

    IPC分类号: A61K399/29 C12P21/00

    摘要: Disclosed herein are the nucleotide sequences, deduced amino acid sequences as well as methods and compositions necessary to elicit immune responses against chronic Hepatitis B infections in animals and humans. Immune response is enhanced by fusing relevant viral antigens with xenotypic immunoglobulin heavy chain region through a peptide linker and producing the fusion proteins in Baculovirus expression system to incorporate high mannose glycosylation. By virtue of the antibody component, the fusion proteins bind to Fc receptors on the surface of antigen presenting cells, are taken up, processed and derived peptides are presented on MHC Class I, which elicit a CTL (Th1) response. In a similar fashion, due to cross priming and presentation on MHC Class II, will elicit a humoral (Th2) response. In addition, disclosed are the methods of cloning, expression and production of the fusion proteins.

    摘要翻译: 本文公开了核苷酸序列,推定的氨基酸序列以及在动物和人中引发针对慢性乙型肝炎感染的免疫应答所必需的方法和组合物。 通过肽接头将相关病毒抗原与异型免疫球蛋白重链区融合并在杆状病毒表达系统中产生融合蛋白以掺入高甘露糖糖基化来增强免疫应答。 由于抗体组分,融合蛋白与抗原呈递细胞表面上的Fc受体结合,被吸收,加工,并且衍生的肽呈现在引起CTL(Th1)应答的MHC I类上。 以类似的方式,由于交叉引物和介绍MHC II类,将引发体液(Th2)反应。 此外,公开了融合蛋白的克隆,表达和产生的方法。